---
schema_version: "secwatch.filing_event.v1"
accession: "0001193805-26-000703"
form_type: "8-K"
ticker: "IMUX"
cik: "0001280776"
company_name: "IMMUNIC, INC."
filed_at: "2026-05-28T11:01:07+00:00"
generated_at: "2026-05-28T11:07:22.487522+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Immunic presents additional Phase 2 CALLIPER data for vidofludimus calcium in progressive MS at CMSC 2026

## Summary
- Late-breaking poster introduces novel unified endpoint Confirmed Disability Change (CDC) that consistently favored vidofludimus calcium over placebo across three statistical models.
- Patient-reported outcomes (PHQ-9) showed no worsening of depressive or suicidal thoughts; treatment satisfaction numerically favored drug over placebo at weeks 48 and 120.
- Safety data from 467 patients: TEAEs comparable (69.4% vs 68.5%), discontinuation due to TEAEs identical at 2.6% in both arms; no Hy's law cases.
- Serious adverse events low and balanced (8.1% vs 6.5%); liver-related TEAEs similar (5.2% vs 5.5%).

## SEC filing metadata
- accession: 0001193805-26-000703
- form_type: 8-K
- ticker: IMUX
- cik: 0001280776
- company_name: IMMUNIC, INC.
- filed_at: 2026-05-28T11:01:07+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1280776/000119380526000703/0001193805-26-000703-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1280776/000119380526000703/e665514_8k-immunic.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193805-26-000703
- JSON: https://secwatch.observer/filing/0001193805-26-000703.json
- Plain text: https://secwatch.observer/filing/0001193805-26-000703.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.